NCT03107897

Brief Summary

In this pilot study, investigators aim to identify patients undergoing TAVR who are at elevated risk for adverse clinical events due to decreased exertional capacity and physical deconditioning. Investigators aim to determine if monitored pre-procedural physical therapy is safe in these patients. Lastly, investigators aim to assess the efficacy of prehabilitation

  1. 1.to improve physical functioning by the time of TAVR and to sustain benefit through 30 days post-procedure; and
  2. 2.to determine its effect on post-procedural length-of-stay, clinical outcomes, and quality of life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 17, 2016

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

March 7, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 11, 2017

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 9, 2020

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2021

Completed
Last Updated

June 9, 2023

Status Verified

June 1, 2023

Enrollment Period

4 years

First QC Date

March 7, 2017

Last Update Submit

June 7, 2023

Conditions

Keywords

TAVRelevated frailty scoreTranscatheter Valve Replacement

Outcome Measures

Primary Outcomes (1)

  • Functional exercise capacity - Change in 6 Minute Walk Test (6MWT)

    Measure: Does prehabilitation improve the subject's functional exercise capacity from first PT assessment to pre-procedure assessment and first PT assessment to one month post-procedure, as measured by the 6MWT?

    One month post procedure

Secondary Outcomes (7)

  • Mobility - Timed Up and Go Test (TUG)

    One month

  • Balance - Four Square Step Test (FSST)

    One month

  • Discharge Disposition

    24-48 hours post procedure

  • Length of stay in the ICU

    TAVR procedure admission

  • Total hospital length of stay

    TAVR procedure admission

  • +2 more secondary outcomes

Study Arms (2)

Pre-procedure standard of care

NO INTERVENTION

No prehab prior to TAVR.

Prehab prior to TAVR procedure.

ACTIVE COMPARATOR

Individuals participate in prehabilitation prior to TAVR.

Other: Pre-habilitation

Interventions

Eight - Twelve visits to physical therapy prior to their TAVR procedure.

Prehab prior to TAVR procedure.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Subject must be ambulatory (with or without an assist device)
  • Subject has severe aortic stenosis and is felt an appropriate candidate for TAVR by the Heart Team.
  • Subject requires 6.0 seconds or longer to complete a 15ft walk test
  • Subject must be able to move between sitting and standing without assistance from another person.
  • Subject has adequate iliac and femoral arterial anatomy to allow for TAVR via transfemoral access
  • Subject is 18 years of age or greater
  • Subject is willing to give consent and participate in the study

You may not qualify if:

  • Subject is incapable of following instructions
  • Subject is unable to meet the minimum required physical therapy visits
  • Subject has other medical conditions rendering it unsafe, in the opinion of the Principal Investigator and physical therapy staff, to perform a 6 Minute Walk Test or physical therapy conditioning prior to TAVR
  • Subject has significant severe un-revascularized epicardial coronary disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wellspan York Hospital

York, Pennsylvania, 17403, United States

Location

MeSH Terms

Conditions

Aortic Valve Stenosis

Condition Hierarchy (Ancestors)

Aortic Valve DiseaseHeart Valve DiseasesHeart DiseasesCardiovascular DiseasesVentricular Outflow Obstruction

Study Officials

  • James Harvey, MD

    Wellspan York Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Comparing individuals who have prehabilitation prior to their TAVR procedure with those that do not.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 7, 2017

First Posted

April 11, 2017

Study Start

August 17, 2016

Primary Completion

August 9, 2020

Study Completion

April 30, 2021

Last Updated

June 9, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will share

All individual participant data defined in the protocol will be collected during trial participation and entered in a secured Electronic Data Capturing System. All data shared or copied shared will only occur after complete deidentification. Participant data will be made available for Annual Data Safety Management Board (DSMB) committee review. The Study Protocol, Informed Consent Form, and applicable Case Report Forms will be available.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Immediately following publication. No End Date
Access Criteria
Researchers who provide a methodologically sound proposal.

Locations